

Final Program



September 17-20, 2007

47th Interscience Conference on Antimicrobial Agents and Chemotherapy *ASM's Premier Annual Meeting on Infectious Diseases and Antimicrobial Agents*



McCormick Place Lakeside Center
Chicago, Illinois
September 17 - 20, 2007 (Monday - Thursday)
Pre-Conference Workshops - Sunday, September 16, 2007

www.icaac.org



Thursday - 224(C2)

224(C2) Poster Session

Multi-Drug Resistant (MDR) Enteric Bacilli: The Enemy Within

Thursday, 9:00 a.m. - 10:00 a.m.

E253

Presentations:

- C2-2060** Characterization of Highly Resistant *Klebsiella pneumoniae*: Report from the 2006 - 2007 BORIS Project.
J. BLOCK^{1,2}, V. LABOMBARDI³, G. PROCOP⁴, J. HATA¹;
¹bioMerieux, Hazelwood, MO, ²bioMerieux, Inc., St. Louis, MO, ³St. Vincent's Hosp., New York, NY, ⁴Univ. of Miami, Miami, FL.
- C2-2061** Dissemination of IMP-Type Metallo- β -Lactamases among *P. aeruginosa* and Emergence of VIM-2 in *Klebsiella oxytoca* in Mexico: Report from the SENTRY Antimicrobial Surveillance Program.
H. S. SADER¹, L. M. DESHPANDE¹, R. MORFIN-OTERO², U. GARZA-RAMOS³, J. SILVA-SANCHEZ³, R. N. JONES¹; ¹JMI Lab., North Liberty, IA, ²Inst. de Patología Infecciosa y Experimental, Guadalajara, Mexico, ³Inst. Natl. de Salud Publ., Cuernavaca, Mexico.
- C2-2062** Decreased Carbapenem Susceptibility among *Klebsiella pneumoniae* (KPN) Isolated in a Tertiary Brazilian Hospital. *
A. F. SANTOS¹, R. C. PICÃO¹, I. SIQUEIRA², L. CORR A², J. PASTERNAK², M. D. V. MARTINO², A. C. GALES¹; ¹UNIFESP, São Paulo, Brazil, ²HIAE, São Paulo, Brazil.
- C2-2063** Nosocomial Outbreak of Carbapenem-Resistant *Klebsiella pneumoniae* Isolates Producing OXA-48 in Turkey.
L. POIREL¹, A. CARRER¹, H. ERAKSOY², A. CAGATAY², S. BADUR², P. NORDMANN¹; ¹Lab. de Bacteriologie, Le Kremlin Bicetre, France, ²Istanbul Univ., Istanbul, Turkey.
- C2-2064** First Detection of *Klebsiella pneumoniae* Harboring GES, β -Lactamases at Tygerberg Hospital, Western Cape, South Africa.
H. ORTH¹, S. MAJALIJA², R. HOFFMANN², G. ELISHA², L. SMITH³, E. WASSERMAN¹; ¹Stellenbosch Univ., Cape Town, South Africa, ²Univ. of Cape Town, Cape Town, South Africa, ³NHLS, Cape Town, South Africa.
- C2-2065** Characterization and Sequence Analysis of Extended Spectrum β -Lactamase Encoding Genes from *E. coli*, *K. pneumoniae* and *P. mirabilis* Isolates Collected During Tigecycline (TGC) Phase 3 Clinical Trials.
M. TUCKMAN, D. KEENEY, R. CAMARDA, S. MANDIYAN, T. SANDS, A. V. RUZIN, P. A. BRADFORD, C. H. JONES; Wyeth, Pearl River, NY.
- C2-2066** Epidemiology of Multi-Drug Resistant *Escherichia coli* in England, 2002 to 2006.
M. LILLIE, A. PEARSON, A. JOHNSON; Hlth. Protection Agency, London, United Kingdom.
- C2-2067** Aquatic Environmental Contamination with ESBL-Producing *Enterobacteriaceae*. *
E. MACHADO^{1,2,3}, T. M. COQUE³, J. C. SOUSA¹, D. SILVA², M. RAMOS², J. ROCHA², H. FERREIRA², L. PEIXE²; ¹UFP, Porto, Portugal, ²Requimte, FFUP, Porto, Portugal, ³HU Ramón y Cajal, Madrid, Spain.
- C2-2068** Effective Risk Factors for Colonization of Extended-Spectrum β -Lactamase Producing Gram-Negative Bacilli in Hospitalized Neonates.
R. MONIR, Z. MOSAYEBI, G. MUSAVI; Kashan Univ. of Med. Sci., Kashan, Iran (Islamic Republic of).
- C2-2069** Extended-Spectrum Beta-Lactamases (ESBLs) Producing *Enterobacteriaceae* in Long-Term Care Facilities (LTCFs): Results of the First Italian Nationwide Prevalence Study.
L. PAGANI¹, A. GOGLIO², M. SPALLA³, L. REGATTIN⁴, E. NUCLEO¹, C. DE LUCA¹, A. GRIGIS², S. BRUSAFERRO⁴;
¹Univ. of Pavia, Pavia, Italy, ²Ospedali Riuniti, Bergamo, Italy, ³IRCCS San Matteo, Pavia, Italy, ⁴Univ. of Udine, Udine, Italy.
- C2-2070** Observation of a Novel ESBL Phenotype (Cefepimease) in *Salmonella* Typhimurium Isolates from Africa and Europe.
D. MORRIS¹, S. KARIUKI², R. GUNTURU³, A. WLODARCZYK¹, C. A. HART⁴, G. CORBETT-FEENEY¹, M. CORMICAN¹; ¹Natl. Univ. of Ireland, Galway, Ireland, ²Kenya Med. Res. Inst., Nairobi, Kenya, ³Kenyatta Natl. Hosp., Nairobi, Kenya, ⁴Univ. of Liverpool, Liverpool, United Kingdom.
- C2-2071** Comparison of Extended-Spectrum, β -Lactamase Producing-(ESBL) and Plasmid-Mediated AmpC, β -Lactamase Producing (AmpC) *Escherichia coli* (EC) from the Canadian Intensive Care Unit Surveillance Study. *
P. J. BAUDRY^{1,2}, K. NICHOL¹, M. DECORBY¹, L. MATASEJE^{3,2}, M. R. MULVEY^{3,2}, D. J. HOBAN^{1,2}, G. G. ZHANEL^{1,2}; ¹Hlth. Sci. Ctr., Winnipeg, Canada, ²Univ. of Manitoba, Winnipeg, Canada, ³Natl. Microbiol. Lab., Winnipeg, Canada.

225(E) Poster Session

Miscellaneous

Thursday, 9:00 a.m. - 10:00 a.m.

E253

Presentations:

- E-2072** Surprising Selective In Vitro Antibacterial Activities of Statins.
H. WIGGIN, H. SALAMA, C. T. PALCU, J. D. SOBEL, R. A. AKINS; Wayne State Univ. Sch. of Med., Detroit, MI.
- E-2073** Unexpected Antimicrobial Effect of Statins.
S. JERWOOD¹, J. COHEN²; ¹Royal Sussex County Hosp., Brighton, United Kingdom, ²Brighton and Sussex Med. Sch., Brighton, United Kingdom.
- E-2074** Broad Antimicrobial Activity of a Mixture of Isothiocyanates (Mustard Oils) In Vitro.
A. CONRAD, H. RICHTER, I. ENGELS, U. FRANK; Univ. Med. Ctr., Freiburg, Germany.
- E-2075** Combination Effect of Epigallocatechin Gallate with Antibiotics on Vancomycin-Resistant *Enterococcus* (VRE) Growth.
Y. YANAGAWA, C. KOHDA, F. MORI, T. SHIMAMURA; Showa Univ., Tokyo, Japan.
- E-2076** Narrow Spectrum Activity and Low Fecal Protein Binding of Opt-80 and its Major Hydrolysis Metabolite (op-1118).
F. BABAKHANI, J. SEDDON, N. ROBERT, A. COMEZ, P. SEARS; Optimer Pharmaceuticals, Inc., San Diego, CA.
- E-2077** A Bacterial Product Obtained by Recombinant Technology is Active against Two Related Gram-Positive Pathogens.
G. SCOARUGHPI, C. LONGHI¹, A. CELLINI¹, R. PAPA¹, A. CARPENTIERI², L. SEGANTI¹, P. PUCCI², A. AMORESANO³, P. COCCONCELLI³, S. GAZZOLA³, M. ARTINI¹, L. SELAN¹;
¹Univ. La Sapienza, Rome, Italy, ²Univ. Federico II, Naples, Italy, ³Univ. Cattolica, Piacenza, Italy.